Deprescribing Glucose-Lowering Therapy in Older Adults with Diabetes: A Systematic Review of Recommendations
(2023) Journal of the American Medical Directors Association — Vol. 24, n° 3, p. 400-402 (2023)
Files
231231SHenrardDeprescribing-Glucose-Lowering-Therapy-in-Older-Ad.pdf
Open Access - Adobe PDF
- 188.31 KB
Details
- Authors
Christiaens, Antoine 
- Abstract
- Overtreatment by glucose-lowering treatment (GLT) is frequent, and may induce harmful hypoglycemic events in older people with type 2 diabetes (T2D), significantly increasing morbidity and mortality.1 Avoiding overtreatment by GLT, either by prescribing appropriate GLT according to their individual risks-benefits balance or by deprescribing GLT, is therefore a key issue in the management of older patients, as recommended by various scientific societies these last years.2 Nevertheless, there is currently no consensus on the definition of GLT overtreatment in older people,3 which prevents a clear statement on which patients should undergo deprescribing of GLT. It is therefore worthwhile to define the profiles of patients for whom GLT should be deprescribed. This systematic review of clinical practice guidelines (CPGs) aimed to compare the recommendations defining profiles of older patients in whom deprescribing GLT is recommended.
- Affiliations
Citations
Christiaens, A., Henrard, S., Sinclair, A. J., Tubach, F., Bonnet-Zamponi, D., & Zerah, L. (2023). Deprescribing Glucose-Lowering Therapy in Older Adults with Diabetes: A Systematic Review of Recommendations. Journal of the American Medical Directors Association, 24(3), 400-402. https://doi.org/10.1016/j.jamda.2022.12.018 (Original work published 2023)